BRIEF

on VALBIOTIS (EPA:ALVAL)

Valbiotis strengthens its financing to support its commercial expansion

Stock price chart of VALBIOTIS (EPA:ALVAL) showing fluctuations.

Valbiotis, a laboratory specializing in cardiometabolic health, announces new financing to support its commercial growth. On November 16, 2026, the company secured €1.65 million in non-dilutive bank loans from its long-standing partners, Société Générale and BNP Paribas, as well as from Bpifrance. A factoring agreement was also signed with BNP Paribas Factor, with an authorized credit limit of €500,000, to manage working capital requirements related to accounts receivable.

The financing secured strengthens Valbiotis' financial flexibility without diluting its shareholding. As of June 30, 2026, the company already had €11.7 million in cash, guaranteeing its financing until the end of 2027. Sébastien Peltier, Chairman of the Board, emphasizes that these funds will allow Valbiotis to effectively support the anticipated increase in pharmacy sales.

R. P.

Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all VALBIOTIS news